Initially hailed as a groundbreaking startup, Theranos attracted significant investment from reputable venture capitalists and partnerships with prominent organizations such as Walgreens. However, in 2015, articles published by the Wall Street Journal raised serious doubts about the accuracy and reliability of Theranos' technology. It was alleged that the company was using commercially available machines for most of its tests instead of their proprietary Edison devices, which raised questions about the validity of the results. These revelations triggered a chain of events leading to the downfall of Theranos. Regulators, including the U. S. Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS), began investigating Theranos and found several violations of laboratory practices. Subsequently, the company faced legal disputes, including a lawsuit from Walgreens and federal criminal charges against Elizabeth Holmes and former company president Ramesh Balwani. Both Holmes and Balwani were indicted on multiple counts, including conspiracy to commit wire fraud and defraud investors. The collapse of Theranos highlighted the risks associated with Silicon Valley's "unicorn" culture and raised questions about the lack of regulatory oversight in the healthcare industry. The company's failure also had significant consequences for investors who had poured millions of dollars into the venture. Although Theranos was once touted as a game-changer in the medical field, its demise exposed the dangers of unchecked claims and the importance of thorough due diligence in evaluating scientific breakthroughs. The scandal surrounding Theranos continues to serve as a cautionary tale for entrepreneurs, investors, and regulators alike.